In FDA double header, regulators also offer a green light to Rigel's fostamatinib
Fast on the heels of Ultragenyx’s big FDA win, Rigel $RIGL came through with an FDA approval for fostamatinib, a new second-line therapy for thrombocytopenia …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
